title: Effects of macrophage colony-stimulating factor (M-CSF) on the mobilization of peripheral blood stem cells.
abstract: We studied the effects of human urinary macrophage colony-stimulating factor (huM-CSF) on the mobilization of peripheral blood stem cells (PBSC) following cytotoxic chemotherapy in 6 patients with acute leukemia. After complete remission (CR) was achieved, two courses of consolidation chemotherapy consisting of an intermediate dose of cytosine arabinoside were administered to the patients. During a recovery phase after each course of consolidation chemotherapy, two successive cycles of leukapheresis were performed every other day. M-CSF was administered intravenously at a dose of 8 x 10(6) U/day during a recovery phase after the second course of consolidation chemotherapy (cytotoxic plus M-CSF mobilization). There was no significant difference in white blood cell (WBC) or platelet recovery between the first and second cycles, regardless of the administration of M-CSF. Furthermore, between cytotoxic and cytotoxic/M-CSF mobilization, significant differences were not observed in the harvest of mononuclear cells (average 1.43 x 10(8)/kg vs 1.62 x 10(8)/kg), granulocyte/macrophage progenitor cells (CFU-GM) (1.82 x 10(4)/kg vs 3.07 x 10(4)/kg) or erythroid progenitor cells (BFU-E) (2.86 x 10(4)/kg vs 2.66 x 10(4)/kg). Thus M-CSF is not effective for expanding a pool of circulating hematopoietic stem cells when administered at a conventional dose during hematologic recovery following chemotherapy.
authors.affiliation: Blood Transfusion Service, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Eto
authors.forename: Y
authors.initials: Y
authors.lastname: Takamatsu
authors.forename: M
authors.initials: M
authors.lastname: Harada
authors.forename: N
authors.initials: N
authors.lastname: Harada
authors.forename: K
authors.initials: K
authors.lastname: Akashi
authors.forename: T
authors.initials: T
authors.lastname: Teshima
authors.forename: S
authors.initials: S
authors.lastname: Inaba
authors.forename: T
authors.initials: T
authors.lastname: Okamura
authors.forename: Y
authors.initials: Y
authors.lastname: Niho
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001773:Blood Cells / Q000473:pathology*; D002465:Cell Movement / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006412:Hematopoietic Stem Cells / Q000473:pathology*; D006801:Humans; D007937:Leukapheresis; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000473:pathology / Q000628:therapy; D016173:Macrophage Colony-Stimulating Factor / Q000494:pharmacology* / Q000652:urine; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000473:pathology / Q000628:therapy
chemical_list: D003561:Cytarabine; D016173:Macrophage Colony-Stimulating Factor; D003630:Daunorubicin